Helix BioPharma Corp. (HBPCF)
OTCMKTS · Delayed Price · Currency is USD
0.6000
0.00 (0.00%)
Jul 30, 2025, 8:00 PM EDT

Helix BioPharma Ratios and Metrics

Millions USD. Fiscal year is Aug - Jul.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jul '25 Jul '24 Jul '23 Jul '22 Jul '21 Jul '20 2016 - 2020
584132259454
Upgrade
Market Cap Growth
0.30%27.81%25.38%-72.89%75.26%13.10%
Upgrade
Enterprise Value
584031269249
Upgrade
Last Close Price
0.600.830.720.773.582.00
Upgrade
PB Ratio
-57.70-626.39-49.71102.32-84.0924.08
Upgrade
P/TBV Ratio
---102.32-29.99
Upgrade
Debt / Equity Ratio
---7.74-2.590.05
Upgrade
Quick Ratio
0.310.720.461.031.012.29
Upgrade
Current Ratio
0.420.920.531.081.042.42
Upgrade
Return on Equity (ROE)
-----1205.79%-
Upgrade
Return on Assets (ROA)
-562.96%-458.65%-166.12%-96.84%-127.23%-184.23%
Upgrade
Return on Capital (ROIC)
---407.18%-150.82%-212.98%-
Upgrade
Earnings Yield
-11.89%-16.43%-14.97%-20.11%-6.86%-12.52%
Upgrade
FCF Yield
-4.91%-9.28%-13.18%-19.94%-7.94%-15.10%
Upgrade
Buyback Yield / Dilution
-23.16%-15.11%-29.26%-8.41%-7.97%-19.75%
Upgrade
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.